by Suzuki et al. (17) has shown that this isoform of STAT6 is central to the JAK3-dependent IL-4 signaling in mast cells. In addition, STAT6 has been shown to regulate IgE/FcRI receptor expression in mast cells (18) . However, the role of STAT6 in IgE receptor-mediated mast cell responses has not been studied. In the present study we examined the role of STAT6 in IgE/FcRI-mediated mast cell responses using in vitro as well as in vivo models.
In this study we report that STAT6 is activated in mast cells upon IgE receptor ligation by an appropriate Ag. Although IgE/ Ag-induced histamine and LTC 4 
releases by STAT6
Ϫ/Ϫ mast cells are normal, STAT6
Ϫ/Ϫ mast cells are significantly impaired in their ability to release cytokines in response to IgE/Ag challenge.
Consistent with these in vitro results, STAT6
Ϫ/Ϫ mice showed severely impaired late phase allergic reactions; however, the early phase cutaneous anaphylactic reaction was not affected.
Materials and Methods

Mice
Male C57BL/6 mice (6 -8 wk old) were purchased from Charles River Laboratories (Wilmington, MA). Breeder pairs of STAT6-null mice (19) were obtained from Dr. J. Ihle (St. Jude Children's Research Hospital, Memphis, TN). Animals were caged in groups of five in a pathogen-free environment in accordance with the rules and regulations of the U.S. Animal Welfare Act and the National Institutes of Health. Animal care and experimental procedures were conducted in agreement with institutional guidelines.
FBS was obtained from HyClone (Logan, UT). LTC 4 ELISA kits were purchased from Cayman (Ann Arbor, MI). Histamine ELISA kits were purchased from Immunotech (Westbrook, ME). Mouse TNF-␣, and IL-6, ELISA kits were purchased from R&D Systems (Minneapolis, MN). The preparations of DNP-BSA (20) and monoclonal anti-DNP-IgE (21) have been described previously. Anti IgE-FITC Ab was purchased from BD PharMingen (San Diego, CA). Dinitrofluorobenzene (DNFB) was obtained from Sigma (St. Louis, MO). HRP-conjugated anti-phosphotyrosine Ab was obtained from Transduction Laboratories (Lexington, KY).
Bacterial strain
The Escherichia coli strain ORN103(pSH2) was cultured in Luria broth containing 50 g/ml chloramphenicol (22, 23) .
Mast cell cultures
Mast cells were cultured from the bone marrow specimens of STAT6-null (STAT6 Ϫ/Ϫ ) and STAT6 ϩ/ϩ control mice in a medium supplemented with 25% WEHI-3 cell supernatant for 3 wk as previously described (12, 24) . Cell density was adjusted to 2 ϫ 10 5 cells/ml on a weekly basis. After 3 wk mast cells were characterized by staining with toluidine blue and Alcian blue (25) . RBL-2H3 cells were a gift from Dr. R. P. Siraganian 
Stimulation of mast cells
Bone marrow mast cells (BMMC) cultured from the bone marrow cells of STAT6 Ϫ/Ϫ or STAT6 ϩ/ϩ mice were sensitized with monoclonal anti-DNP IgE Ab (0.24 mg/ml) for 1 h at 37°C. Unbound IgE was removed by washing the cells with PBS. After washing the BMMC were resuspended in RPMI-HEPES buffer at a cell density of 1 ϫ 10 6 /ml. The cells were challenged with 20 ng/ml DNP-BSA at 37°C.
RBL-2H3 cells were sensitized with monoclonal anti-DNP IgE Ab (0.24 mg/ml) overnight at 37°C in a 48-well tissue culture plate. Unbound IgE was removed by washing the cells with PBS. After washing the PIPESbuffered saline containing 1 mM calcium chloride was added to the monolayers of the RBL-2H3 cells. The cells were challenged with 20 ng/ml DNP-BSA for 30 min at 37°C. The plate was centrifuged at 200 ϫ g for 10 min at 4°C. Supernatants were removed, and the cell pellets were lysed in lysis buffer.
To examine the role of STAT6 in E. coli-mediated mast cell responses, BMMC cultured from the bone marrow specimens of STAT6 Ϫ/Ϫ or STAT6 ϩ/ϩ mice were resuspended in RPMI-HEPES buffer at a cell density of 1 ϫ 10 6 /ml. The cells were challenged with E. coli 1 ϫ 10 8 ORN103(pSH2) at 37°C for 1 h. After incubation the cells were centrifuged at 200 ϫ g for 10 min at 4°C. TNF-␣ levels were quantitated in cell-free supernatants.
Western blot analyses of mast cell lysates
Mast cells were sensitized with IgE and stimulated with Ag. Cells were harvested, lysed (10 mM Tris (pH 7.6), 100 mM NaCl, 1% Nonidet P-40, 10% glycerol, 50 mM NaF, 100 M Na 3 VO 4 , 50 g/ml PMSF, 10 g/ml aprotinin, and 10 g/ml leupeptin), and the kinases were immunoprecipitated from the lysates, as reported using Abs directed against STAT6 (27, 28) . Commercially available M-20 Abs reactive with STAT6 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Immunoprecipitations and immunoblotting using the ECL chemiluminescence detection system (Amersham Life Sciences, Arlington Heights, IL) were conducted as described previously (12) .
Mediator release assays
Histamine content in cell-free supernatants and in the solubilized cell pellets was estimated using a commercially available enzyme immunoassay (29) . LTC 4 levels were estimated in cell-free supernatants by immunoassay (24) . TNF-␣ and IL-6 levels were estimated in cell-free supernatants using commercially available enzyme immunoassays.
IgE binding assay
Mast cells were incubated with 0.24 mg/ml monoclonal anti-DNP IgE Abs for 1 h at 37°C. The cells were washed thoroughly three times with saline containing 1% BSA and labeled with 10 g/ml anti-IgE-FITC (BD PharMingen) for 30 min at 4°C. After washing the cells were analyzed by flow cytometry for FcRI receptor expression.
Passive cutaneous anaphylaxis
To examine the role of STAT6 in FcRI-mediated passive cutaneous anaphylaxis in mice, dorsal sides of the ears of STAT6 ϩ/ϩ and STAT6
Ϫ/Ϫ mice were injected intradermally with 20 ng anti-DNP IgE (left ears) or PBS (right ears) in a 20-l volume using a 30-gauge needle, as previously described (30) . After 24 h mice were challenged with 100 g Ag (DNP-BSA) in 200 l 2% Evans blue dye i.v. Mice were sacrificed 30 min after the Ag challenge. For quantitation of Evans blue dye extravasation as a measure of anaphylaxis-associated vascular hyperpermeability, 8-mm skin specimens were removed from the ears of mice, minced in 2 ml formamide, and incubated at 80°C for 2 h in water bath to extract the dye. The absorbance of the extracted dye was read at 590 nm. In some experiments, mice were injected i.v. with 0.5 g anti-DNP IgE. After 24 h a skin reaction was elicited by painting 25 l 0.15% DNFB on both the sides of the ear as has been described previously (31) . Ear edema was measured at the times indicated by plythesmometer.
FIGURE 1.
Activation of STAT6 in mast cells after IgE receptor crosslinking. To study IgE/Ag-induced activation of STAT6 in mast cells, RBL-2H3 cells were sensitized with monoclonal anti-DNP IgE and then challenged with DNP-BSA for the times indicated. Mast cells were lysed using a Nonidet P-40 lysis buffer, and STAT6 immune complexes from these cell lysates were subjected to anti-phosphotyrosine (APT) Western blot analysis to examine the phosphorylation of the STAT6 (upper panel). In parallel, STAT6 immune complexes were examined by anti-STAT6 immunoblotting (lower panel) to confirm that the increased tyrosine phosphorylation in APT blots was not due to differences in the amount of STAT6 immunoprecipitated. 
FIGURE 2. Characterization of STAT6
Results
IgE receptor/FcRI-mediated activation of STAT6 in mast cells
We first examined IgE/FcRI receptor-mediated STAT6 activation in mast cells. To achieve this, anti-DNP IgE-sensitized RBL-2H3 mast cells were challenged with Ag (DNP-BSA) for indicated times and phosphorylation of STAT6 was examined by Western blot analysis. As shown in Fig. 1 , cross-linking of the IgE receptors on mast cells resulted in enhanced tyrosine phosphorylation of a 94-kDa STAT6 protein.
Role of STAT6 in IgE/FcRI receptor-mediated in vitro mast cells responses
We next sought to determine the physiologic significance of STAT6 activation in IgE/Ag-stimulated mast cells using STAT6 knockout (STAT6 Ϫ/Ϫ ) mice. As shown in Fig. 2A , similar numbers of mast cells were obtained from bone marrow specimens of STAT6 ϩ/ϩ and STAT6 Ϫ/Ϫ mice after 3 wk of culture in medium supplemented with IL-3. STAT6
Ϫ/Ϫ mast cells displayed typical staining pattern with toluidine blue (data not shown). The surface IgE/FcRI receptor expression levels of STAT6 ϩ/ϩ and STAT6 Ϫ/Ϫ mast cells were virtually identical (Fig. 2B) , reminiscent of the findings by Ryan et al. (18) . Thus, STAT6 deficiency does not affect mast cell population size, morphology, or IgE/ FcRI receptor expression levels.
We metabolite LTC 4 , and cytokine secretion was measured. No significant differences were detected in IgE/Ag induced histamine release (Fig. 3A) or LTC 4 release (Fig. 3B ) from STAT6 ϩ/ϩ vs STAT6 Ϫ/Ϫ mast cells. However, the release of TNF-␣ (Fig. 3C) as well as the release of IL-6 (Fig. 3D) Fig. 3E , STAT6 deficiency did not affect the TNF-␣ release from mast cells exposed to E. coli. Thus, STAT6 plays an important role in IgE receptor/FcRI-mediated, but not E. colimediated, mast cell cytokine release.
Role of STAT6 in IgE/FcRI receptor mediated in vivo mast cells responses
Mast cell-derived mediators produce a biphasic allergic reaction. A number of inflammatory mediators, including histamine, serotonin, and LTs, that are released immediately after mast cell activation have been shown to play a key role in induction of vascular permeability changes (30, 33, 34) , whereas mast cell-derived cytokines such as IL-4, IL-5, GM-CSF, and TNF-␣ regulate the development of late phase inflammatory responses (35) . We first examined the effect of STAT6 deficiency on vascular permeability in a well-characterized murine model of passive cutaneous anaphylaxis (PCA) (30) . STAT6
ϩ/ϩ and STAT6 Ϫ/Ϫ mice were primed with intradermal injections of anti-DNP-IgE. Twenty-four hours later mice were challenged with Ag (DNP-BSA), and Evans blue dye extravasation was measured as a surrogate marker of plasma exudation. There was no significant difference in the PCA reaction between STAT6 ϩ/ϩ and STAT6 Ϫ/Ϫ mice (Fig. 4) , which is in accord with our in vitro data showing that STAT6 deficiency does not affect histamine and LTC 4 release from mast cells. We next used a well-characterized mouse model of late phase allergic reactions (31, 35) , which depends on mast cell-derived TNF-␣ (36). STAT6 ϩ/ϩ and STAT6 Ϫ/Ϫ mice were sensitized i.v. with 50 g anti-DNP IgE. Twenty-four hours later a solution of 0.15% DNFB was painted on both sides of the left ear. Contralateral ears were painted with vehicle (acetone) alone. As shown in Fig. 5A  STAT6 Ϫ/Ϫ mice showed significantly less edema than STAT6 ϩ/ϩ mice. We also examined the effects of STAT6 deficiency on IgE/ hapten-induced histological changes in ear skin. The control ear skin (IgE/vehicle) typically has a two-or three-cell layer-thick epidermis and contains a few scattered inflammatory cells in the dermis (Fig. 5B) . The ear skin of STAT6 ϩ/ϩ mice showed thickened epidermis with four or five cell layers, and a large number of neutrophils were accumulated in the dermis (Fig. 5B) . In contrast, the ear skin of STAT6 Ϫ/Ϫ mice showed reduced epidermal cell thickening with fewer inflammatory cells than STAT6 ϩ/ϩ mice. A histopathological analysis of ear skin of IgE/DNFB-challenged STAT6 ϩ/ϩ and STAT6 Ϫ/Ϫ mice was also performed to evaluate the magnitude of polymorphonuclear (PMN) cell infiltration. The tissue sections were scored on a scale of 1ϩ to 3ϩ; 1ϩ was considered mild infiltration (1-10 PMN/section), 2ϩ was considered moderate infiltration (11-20 PMN/section), and 3ϩ was considered marked infiltration (21 or more PMN/section). Three of four IgE/DNFB-challenged STAT6 Ϫ/Ϫ mice showed mild (1ϩ) PMN infiltration (75%), whereas one STAT6 Ϫ/Ϫ mouse showed no PMN infiltration (25%). Of five IgE/DNFB-challenged control STAT6 ϩ/ϩ mice, three showed marked (3ϩ) PMN infiltration (60%), one moderate (2ϩ), and one mild (1ϩ). These results demonstrate that STAT6 is a key regulator of IgE receptor-mediated late phase allergic responses of mast cells in vivo.
Discussion
STAT6 has been known as a regulator of IL-4-dependent immune responses (15, 19, 37, 38) . It has also been shown to play an essential role in allergic airway inflammation by regulating Th2-type cytokine production of T cells (39 -41) . In the present study we examined the role of STAT6 in IgE receptor/FcRI-mediated mast cell responses in experimental models of allergic inflammation. Our results demonstrate that STAT6 plays a pivotal role in IgE receptor/FcRI-mediated cytokine release from mast cells.
STAT6-deficient bone marrow mast cells from STAT6 Ϫ/Ϫ mice released significantly less TNF-␣ and IL-6 than wild-type mast cells from STAT6 ϩ/ϩ mice upon cross-linking of their IgE receptor/FcRI. The poor cytokine response of STAT6 Ϫ/Ϫ mast cells was not due to reduced IgE receptor expression levels, because STAT6 ϩ/ϩ and STAT6 Ϫ/Ϫ mast cells expressed similar levels of IgE receptor/FcRI on their surface, which is in accord with the findings of Ryan et al. (18) , who previously reported that STAT6 deficiency does not affect mast cell IgE receptor expression. The impaired cytokine release from STAT6 Ϫ/Ϫ mast cells was restricted to IgE receptor/FcRI stimulation, because STAT6-deficient mast cells released normal amounts of TNF-␣ in response to bacterial stimulation.
In an effort to determine the significance of impaired mast cell cytokine response in STAT6 Ϫ/Ϫ mast cells, we used a mouse model of cytokine-dependent late phase reaction. In this model mice are sensitized with IgE and subsequently challenged with DNFB (42) . This challenge results in a biphasic inflammatory response, an early phase that peaks at 1 h, and a late phase that peaks at 24 h (42). Many studies indicate that the cutaneous late phase reaction is in part mediated by mast cell-derived cytokines (35, 36) . Mast cell-derived TNF-␣ is known to play a critical role in late phase reactions of hypersensitivity (36) . However, since STAT6 deficiency also affects the cytokine responses of other inflammatory cells, such as macrophages (43) , a significant contribution of cells other than mast cells in the impaired late phase allergic responses of STAT6 Ϫ/Ϫ mice cannot be excluded. Histamine and LTs are critical for mast cell-mediated vascular permeability changes, a hallmark of early phase allergic reaction (30, 33, 34) . Notably, STAT6 deficiency of mast cells did not affect the IgE receptor-mediated in vitro histamine or LTC 4 release from mast cells. When we compared the IgE/Ag-induced vascular permeability changes between STAT6 ϩ/ϩ and STAT6 Ϫ/Ϫ mice in an in vivo mouse model of passive cutaneous anaphylaxis, we noticed no significant differences. Thus, STAT6 deficiency impairs late (but not acute) phase allergic responses by selectively impairing the release of proinflammatory cytokines such as TNF-␣.
While expanding our knowledge of the physiologic significance of STAT6, our study provides novel insights into the complex signal transduction network of mast cell activation. Our efforts to date to reconstitute STAT6 Ϫ/Ϫ mast cells with wild-type or mutant STAT6 have failed. Therefore, the role of STAT6 protein in mast cell functions remains to be further elucidated at the cellular level using STAT6-reconstituted STAT6 Ϫ/Ϫ mast cells. Further studies involving transfection of STAT6 Ϫ/Ϫ mast cells with appropriately designed mutant STAT6 proteins would also help us determine which portions of STAT6 participate in signal transduction pathways stimulated by engagement of the high affinity IgE receptor of mast cells.
